Synthesis and biological evaluation of radio-iodinated benzimidazoles as SPECT imaging agents for NR2B subtype of NMDA receptor. by Fuchigami Takeshi et al.
Synthesis and biological evaluation of radio-iodinated benzimidazoles as SPECT 
imaging agents for NR2B subtype of NMDA receptor 
 
Takeshi Fuchigamia,c, Hiroshi Yamaguchib, Mikako Ogawaa, Le Biaoa, Morio 
Nakayamac, Mamoru Haratakec, Yasuhiro Magataa,b* 
 
aPhoton Medical Research Center, Hamamatsu University School of Medicine, 
Hamamatsu 431-3192, Japan 
bMolecular Imaging Frontier Research Center, Hamamatsu University School of 
Medicine, Hamamatsu 431-3192, Japan 
cGraduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, 
Nagasaki 852-8521, Japan 
 
*corresponding author: 
Yasuhiro Magata,  
Photon Medical Research Center, Hamamatsu University School of Medicine, 






In this study, the benzimidazole derivatives were synthesized and evaluated as 
imaging agents for the NR2B subype of NMDA receptor. Among these ligands, 
2-{[4-(4-Iodobenzyl) piperidin-1-yl]methyl} benzimidazol-5-ol (8) and N-{2-[4-(4- 
Iodobenzyl)-piperidin- 1-ylmethyl]benzoimidazol -5-yl}-methanesulfonamide (9) 
exhibited high affinity for the NR2B subunit (Ki values; 7.28 nM for 8 and 5.75 nM for 
9). In vitro autoradiography experiments demonstrated high accumulation in the 
forebrain regions but low in the cerebellum for both [125I]8 and [125I]9. These regional 
distributions of the radioligands correlated with the expression of the NR2B subunit. 
The in vitro binding of these ligands was inhibited by NR2B antagonist but not by other 
site ligands, which suggested the high selectivity of [125I]8 and [125I]9 for the NR2B 
subunit. In mice, the regional brain uptakes of [125I]8 and [125I]9 at 5–180 minutes after 
administration were 0.42–0.56 and 0.44–0.67% dose/g, respectively. The brain to blood 
ratio of [125I]8 at 180 minutes was reduced by 34% in the presence of non-radioactive 
ligands and by 59% in the presence of the NR2B ligand Ro-25,6981. These results 
indicated that [125I]8 could be partially bound to the NR2B subunit in vivo. Although the 
brain uptake of these benzimidazole derivatives was too low to allow for in vivo SPECT 
imaging, these compounds might be useful scaffolds for the development of imaging 
probes specific for the NMDA receptors.  
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The N-methyl-D-aspartate (NMDA) receptor, a member of the glutamate 
receptors, plays an important role in the neurotransmission function of the central 
nervous system (CNS).1 Overactivation of the NMDA receptor, however, is thought to 
cause various disorders, such as ischemia, stroke, Parkinson’s Disease, Alzheimer’s 
Disease, Huntington’s Disease, and schizophrenia.2-6 NMDA receptors are heteromers, 
which contain an NR1 subunit and one or more types of the different NR2 subunits 
(NR2A-D).7 NR1 subunit has only one gene (8 splice variants) with ubiquitous 
distribution in the brain. NR2 subunits, on the other hand, exhibit distinct distribution in 
the brain, which determine the synaptic localization and function of the NMDA receptor. 
The NR2A subunit is widely distributed throughout the brain; but, the NR2B subunit is 
confined in the forebrain region, including the cerebral cortex, hippocampus, and 
olfactory bulb. The NR2C and NR2D are localized in the cerebellum and 
diencephalus/lower brain stem, respectively. The NR2A and NR2B are known to be the 
predominant NR2 subunits in the adult forebrain.8 It is suggested that NR2A-containing 
NMDA receptors are involved in prosurvival signaling; thereby, they exert a 
neuroprotective action against glutamate receptor-dependent apoptotic neuronal 
injuries.9-11 On the other hand, an increasing number of reports have demonstrated the 
importance of the NR2B subunit in determining the pharmacological and functional 
properties of the NMDA receptor. The NR2B has been implicated in modulating 
functions, such as learning, memory processing, and feeding behaviors, as well as being 
involved in a number of human disorders.12 It is suggested that activation of the 
NR2B-containing NMDA receptor initiates apoptotic signaling cascades and promotes 
neuronal death.9-11 Recent progress in molecular biology revealed the in vitro function 
of the NR2B-containing NMDA receptor considerably. However, its function in the 
living brain is not well understood due to the lack of visualizing method in vivo. 
positron emission tomography (PET) and single photon emission computed 
tomography (SPECT) are the most efficient imaging methods for in vivo measurement 
of neurotransmitter receptors and enzymes in the brain. Our study, as well as other 
studies, have developed several radioligands for the NR2B subunit of the NMDA 
receptor (Fig. 1). These ligands showed similar accumulation pattern with the 
localization of expression of the NR2B subunit only under in vitro condition but not in 
vivo.13-19 Among these ligands, only [11C]EMD-95885 showed significant reduction of 
the in vivo brain uptake by treatment with the NR2B ligand.16 Although the inhibition 
pattern was inconsistent with NR2B expression, this chemical structure might be a 
useful lead for the development of potential imaging probes. Recently, a new series of 
benzimidazole derivatives 1 and 2 are developed as novel NR2B antagonists (Fig. 2), 20 
which have similar chemical structures with EMD-95885. For example, compound 1a 
showed excellent affinity for the NR2B subunit (Ki= 1.5 nM). Introduction of a 
hydrophobic substituent into the R2-position of benzimidazoles, such as compound 1, 
maintained receptor affinity.20-22 On the bases, we designed new SPECT imaging agents, 
which introduced 125I atom into the R2-position of benzimidazoles. In this study, [
125I] 
labeled benzimidazole derivatives were synthesized and the in vitro binding properties 
and in vivo brain uptake characteristics in rodents were examined. It is reported that 11C 
labeled 4-acetoxy derivative of L-703,717, which is a PET ligand for glycine site of 
NMDA receptor, can be a substrate of P-gp23. However it is not clear if the NR2B 
ligands are substrates of P-gp. Some of NR2B ligands such as ifenprodil and 
benzidazoles in this series have acidic phenol group. It has been shown that organic 
anion transporter is responsible for the elimination of several acidic drugs from the 
brain across the BBB24. Therefore the effect of P-gp and OAT on the in vivo uptake of 
[125I]benzimidazoles were also investigated. 
  
2. Results and discussion 
 
2.1. Chemistry 
     Based on the previous structure-activity relationship studies, 20-22 the SPECT 
imaging agent candidates 8, 9, and 13 were designed, in which an iodine atom was 
introduced into the 4’-position (R2-position) of benzyl- or phenoxy-piperidine group of 
benzimidazoles. Lead compound 1a was synthesized according to the literature.20 The 
4’-Iodo substituted benzylpiperidine derivatives (8 and 9) were synthesized as shown in 
Scheme 1. Alkylation of compound 325 with ethyl bromoacetate gave 4 (71 % yield), 
followed by a bromo-to-tributyltin exchange reaction gave tributyltin derivative 5 for 
yields of 53 %. Compound 5 was allowed to react with iodine in CCl4 to give the iodo 
derivative 6 (68 % yield). Compound 6 was hydrolyzed, followed by general amide 
coupling reaction with the corresponding phenylenediamines. Dehydration of the 
amidated products in acetic acid at reflux gave the benzimidazoles 7 and 9 for yields of 
55 % and 53 %, respectively. Compound 7 was converted to 8 by desmethylation with 
HBr (63 % yield). The target iodo phenoxypiperidine derivative (13) was synthesized 
as shown in Scheme 2. Phenoxypiperidine 11 was synthesized according to the method 
of Scheme 1 starting from compound 1026 for yield of 45 %. Benzimidazole 12 was 
obtained by the same procedure for the synthesis of compound 7 for yield of 73 %. 
Finally, compound 12 was desmethylated by BBr3 to give 13 (77 % yield).      
 
2.2. In vitro binding assays 
The binding affinities (Ki values) of benzimidazole derivatives for the NR2B 
subunit of NMDA receptor were evaluated with displacement studies of the typical 
NR2B antagonist, [3H]ifenprodil, to rat cortical synaptic membranes according to the 
literature.27  Trifluoroperazine was used to block the binding of [3H]ifenprodil in rat 
brain membranes to sites other than the NMDA receptors. As shown in Table 1, lead 
compound 1a showed excellent affinity (Ki= 3.09 nM) for the NR2B subunit, which 
was consistent with the results by using hNR1a/NR2B receptors expressed in Ltk- cells 
(Ki= 1.50 nM) reported in the literature.20 Introduction of an iodine atom in R2 resulted 
in a slight reduction of binding affinity; however, high affinity for the NR2B subunit 
(Ki values; 7.28 and 5.75 nM for 8 and 9, respectively) was maintained. On the other 
hand, phenoxypiperidine benzimidazole 13 exhibited a 4.5-fold lower affinity (Ki= 32.5 
nM) than compound 8. These results suggested that the presence of phenoxypiperidine 
frame, instead of the benzylpiperidine, negatively influenced the in vitro binding 
affinity for this class of compound. In the recent report, the indole-carboxamide 
derivatives, with an oxygen atom substituted in the X-position, have several-fold lower 
affinity than the compounds with methylene group. On the contrary, comparable 
affinities were shown between benzimidazole-carboxamide derivatives substituted with 
methylene group and oxygen atom in X-position.22 Therefore, it might be difficult to fit 
the binding space for phenoxypiperidine derivatives in the NR2B antagonist binding 
site. Since 8 and 9 had high affinity for the NR2B subunit of the NMDA receptor, these 
ligands were selected to carry out further biological evaluations on the corresponding 




Trimethyltin precursors 14 and 15 were synthesized from 8 and 9, respectively, 
by an iodo-to-trimethyltin exchange reaction (53 % yield for 14 and 97 % yield for 15). 
To obtain [125I]8 and [125I]9, the corresponding trimethyltin precursors were allowed to 
react with [125I]NaI (carrier-free) in the presence of H2O2 and HCl at room temperature 
for 40 min by a similar method in the literature28 (Scheme 3). The resulting I-125 
labeled crude products were purified by HPLC. The radiochemical yields based on 
[125I] NaI were 85-90 and 78-81 %, for [125I]8 and [125I]9, respectively.  
 
2.4. In vitro autoradiography 
 
     In vitro regional distributions of [125I]benzimidazoles on the rat brain sections 
were evaluated by a method mentioned in the literature.13 As shown in the 
autoradiogram in Figure 3, both [125I]8 and [125I]9 showed high accumulation in the 
forebrain region (cerebral cortex, hippocampus), which is an NR2B-rich region, and 
lower uptake in the cerebellum, which is an NR2B-poor region (Fig. 3A and B). These 
distribution patterns were similar to [3H]CP-101,606,29 as well as to the mRNA 
distribution of the NR2B subunit.30 Nonspecific binding was determined in the presence 
of corresponding nonradioactive benzimidazoles (10 μM), which resulted in a 
significant decrease in [125I]8 and [125I]9 accumulations in the forebrain region 
compared with total binding as visualized in Figure 3C and D and quantified in Figure 
3E and F, respectively. Almost no specific binding of both ligands exists in the 
cerebellum. The specific binding of [125I]8 was higher than [125I]9 in the forebrain 
regions (Fig. 3E and F). These [125I]benzimidazoles showed similar binding property 
with C-11-labeled analog of CP-101,606, which is a high-affinity radioligand for the 
NR2B subunit.13 However, their specific bindings were lower than the [11C]CP-101,606 
analog. The high lipophilic property of [125I]8 and [125I]9 was attributed to. The logD7.4 
values of 8 and 9 were 3.95 and 3.54, respectively as shown in Table 1, which are higher 
than the [11C] CP-101,606 analog (log P= 0.75).  
In order to investigate the specific binding of [125I]8 and [125I]9 to the NR2B 
subunit of the NMDA ion channel, in vitro inhibition studies on rat brain region using 
Ro-25,6981 (NR2B antagonist) were carried out. Since it is reported that several 
ifenprodil-like antagonists bind to α1-adrenergic and σ receptor,31,32 the effects of 
prazosin (α1-adrenergic receptor antagonist) and DTG (σ receptor antagonist) in 
blocking these receptors in the inhibition studies were examined. In result, the in vitro 
bindings of [125I]8 and [125I]9 in the cerebral cortex and hippocampus were inhibited 
only by the NR2B selective antagonist, Ro-25,6981, as shown in Table 2. On the 
contrary, no ligands inhibited the bindings in the cerebellum. These results indicated 
that [125I]8 and [125I]9 selectively bind to the NR2B subunit. Therefore, this study 
attempted to carry out in vivo studies to validate the effectiveness of these [125I] 
benzimidazoles as SPECT imaging agents for the NR2B-subunit-containing NMDA 
receptor.  
 
2.5. In vivo pharmacology 
 
     The biodistribution studies of [125I]8 and [125I]9 were performed by using normal 
mice and the results were shown in Table 3. Initial brain uptake of [125I]8 was 0.21 % 
dose/g at 0.5 min after intravenous injection; whereas, the uptake of [125I]9 was 
0.32 %dose/g at the corresponding time. Both ligands showed very low brain to blood 
ratio (0.07) at 0.5 min. Radioactivity of [125I]8 and [125I]9 in the brain increased with 
time and peaked at 180 min after administration (0.56 % and 0.67 % dose/g, 
respectively). Accordingly, brain to blood ratio of these ligands rose to 1.99 and 1.23 at 
180 min, respectively. High hepatic uptake of [125I]8 and [125I]9 was observed, which 
peaked to 32.22 % and 17.81 % dose/g at 180 min, respectively. The amount of 
radioactivity of these tracers in the kidney was also high (5.35-12.20 and 3.26-15.23 % 
dose/g, respectively). The distribution patterns in peripheral tissues could be attributed 
to the high lipophilic property of these [125I]benzimidazoles. These ligands showed 
almost homogenous brain distribution at 5-360 min after intravenous administration 
(Fig 4), which was inconsistent with the localization of expression of the NR2B subunit. 
The results for [125I]benzimidazoles were similar to other radioligands for the NR2B 
subunit.13-16 Metabolisms of [125I]8 and [125I]9 in the mouse brain were analyzed by 
radio-TLC of brain homogenates obtained at 180 min post-injection; and 77 % and 
85 %, respectively, of the parent compounds remained unchanged (data not shown). 
Thus, metabolism could have minimal effect the distribution pattern of [125I]8 and 
[125I]9. The results of this study showed that in vitro specific binding and in vivo brain 
uptake to blood radioactivity ratio of [125I]8 were higher than [125I]9. Therefore, in vivo 
experiments on [125I]8 were further performed.  
The specificity of regional brain binding of [125I]8 for the NR2B subunit was 
studied by blocking studies using non-radioactive 8 and Ro-25,6981 (3 mg/kg, 
intravenously), which were administered 30 min prior to injection of the radioligand. 
Since brain uptake of [125I]8 peaked at 180 min as shown in Table 3, regional brain 
distribution at 180 min after the radiotracer injection was determined. As shown in 
figure 5, pre-injection of non-radioactive 8 resulted in a significantly increased blood 
radioactivity of [125I]8 (P < 0.01) compared with the control group. Altogether, the liver 
uptake was significantly decreased (P < 0.01). On the other hand, the brain uptake was 
increased slightly. Pre-administration of the NR2B selective antagonist, Ro-25,6981, 
had no effect on blood radioactivity of [125I]8. The hepatic uptake of [125I]8 was slightly 
increased but the regional brain uptake was slightly decreased. It should be noted that 
both groups treated with cold 8 and Ro-25,6981 showed a markedly lower brain to 
blood ratio of [125I]8 than the control group (Fig. 5D). Considering these results, [125I]8 
could have specific binding component in the NR2B subunit under in vivo condition, 
which was similar to [11C]EMD-95885.16 However, both [125I]8 and [11C]EMD-95885 
demonstrated reduced radioactivity in the NR2B poor region, cerebellum, even in the 
presence of NR2B ligands, which was unexplainable.  
On the other hand, the brain uptake of commonly used PET radioligands, such as 
[11C]raclopride and [11C]DASB, was higher than [125I]8.33,34 Considering these facts, the 
brain permeability of [125I]8 could be inadequate for the visualization of NR2B subtype 
of the NMDA receptor by SPECT. All of the radioligands for NR2B subunit including 
benzidazoles in this report were inadequate BBB permeability. Log P (or Log D7.4) 
values of [125I]8, [125I]9 and 11C labeled CP-101,606 analog were 3.95, 3.54 and 0.7513. 
Log P values of 5-[3-(4- benzylpiperidin- 1-yl) prop-1-ynyl]-1,3- dihydrobenzoimidazol 
-2-[11C]one14 and [11C]EMD-9588516 were not reported, however, calculated by 
ChemDraw Ultra to be 3.36 and 3.40, respectively. These ligands are not within the 
optimal range (1.0–3.0) for compounds expected to penetrate the BBB.35 Therefore log 
P value might be one of the reasons that the ligands showed low brain uptake. Another 
reason was thought to be high uptake of NR2B ligands in lung. The basic piperidine 
group in the ligands might cause these accumulation proclivities. Alternatively, lower 
molecular weight derivatives might be necessary to increase BBB permeability. 
Another likely reason for the low uptake could be the excretion from brain tissue 
by the efflux systems of the BBB. It has been shown that many radioligands for 
mapping neuroreceptors are substrates for P-gp.36-38 It is reported that several acidic 
drugs are eliminated by the OAT from the brain across the BBB.24 Since the phenolic 
group in 8 has acidic moiety, there is a possibility that the brain uptake of [125I]8 is 
effluxed by OAT. Therefore, the effect of P-gp and OAT to the in vivo brain uptake of 
[125I]8 was analyzed.  
Pretreatment with CsA (Cyclosporine A) (substrate of P-gp, 50 mg/kg) or 
probenecid (substrate of OAT, 200 mg/kg) by intravenous injection on mice tail vein 30 
min before [125I]8 administration was followed by examination of biodistribution 
180min later. As shown in Table 4, pretreatment with CsA resulted in the reduction of 
blood radioactivity level of [125I]8 but increase in the brain uptake in the CsA group 
compared with the control group. Therefore, the brain to blood ratio was 1.6-fold higher 
than the control group. Although P-gp is known to be present in the liver and kidney,39 
the effect of CsA to the uptake of [125I]8 in the liver and kidney is nil. In contrast, 
pretreatment with probenecid increased the brain uptake but decreased the blood 
radioactivity level of [125I]8. The brain to blood ratio in the probenecid group was 
1.3-fold higher than the control group. The uptake of [125I]8 in the kidney was 
significantly reduced relative to the control group. The hepatic uptake of [125I]8, on the 
other hand, demonstrated no reduction by treatment with probenecid (Table 5). It is 
reported that probenecid is the substrate of OAT1 and 3. OAT1 is mainly expressed in 
the kidney and OAT3 in the kidney and brain. OATs play a role in the renal influx of 
probenecid.40,41 Therefore, this study indicated that [125I]8 may be a substrate of OATs in 
the brain and kidney. Although the extent of transport via P-gp and OAT is thought to be 
minimal, a certain amount of [125I]8 that enters the brain might serve as substrate of 
P-gp and OAT. Since it is reported that numerous structurally and pharmacologically 
unrelated lipophilic and amphipathic organic compounds are substrate of P-gp,42 the 
structural relationship between benzimidazoles and P-gp substrate is not elucidated. The 
introduction of a non-acidic group instead of a hydroxyl group in the benzimidazole 
skeleton of [125I]8 is expected to reduce the efflux by OAT. Furthermore, reduced 
lipophilic property of [125I]8 should be necessary to increase BBB permeability.  
Another problem is the homogeneous distribution of [125I]8 and [125I]9 observed 
in the brain tissues under in vivo condition, which was quite different from in vitro 
results. Various factors might be present under in vivo condition such as nonspecific 
binding to capillary endothelial cells or other region. It is unclear whether the 
radioactivity of regional brain is present in the target site or peripheral sites. However 
the benzimidazoles with optimized log P values might decrease an accumulation in 
peripheral region.  
Similar to this study, previously reported imaging agents for NR2B subunit of 
NMDA receptor showed consistent accumulation pattern with the expression of NR2B 
subunit and high specificity to NR2B rich region only under in vitro condition but not in 
vivo.13-19 Moreover, similar binding characters were observed in the radioligands for 
other binding sites of NMDA receptor, such as ion-channel site43,44 and glycine site45-47. 
Kew et. al. suggested that ifenprodil might exhibit higher affinity for the agonist-bound 
activated and desensitized states of the NMDA receptor, respectively, relative to the 
resting, agonist-unbound state.48 Furthermore, Mott et. al. demonstrated that NR2B 
antagonists were much more potent as a neuroprotectant at pH 6.5 than at pH 7.5.48 The 
pH of ischemic tissue is as low as 6.5.50 In like manner, it is reported that 
[125I]CNS-1261, a radioligand for ion-channel site of NMDA receptor, showed higher 
uptake in the ischemic rat brain than normal region.51 In lieu with these reports, it is 
conjectured that the different biodistribution patterns of radioligands for the NR2B 
subtype of the NMDA receptor could be observed between normal condition and 
overactivated state, such as pathological stage.  
Since [125I]8 and [125I]9 showed low brain uptake and homogeneous brain 
distribution, these ligands were unsuitable for SPECT imaging of cerebral NMDA 
receptors. However, it should be noted that [125I]8 may have specific binding 
component in the NR2B subunit in vivo. The present study indicated that benzimidazole 
derivatives may be potential lead compounds for developing novel imaging agents for 
the NR2B subtype of NMDA receptors. Further structure activity relationship studies 




Our study has developed high-affinity benzimidazole derivatives 8 and 9 as new 
SPECT ligand candidates for NR2B subunit of the NMDA receptor. In vitro 
autoradiography experiments demonstrated that [125I]8 and [125I]9 showed NR2B 
selective binding in the rat brain slices. Although [125I] benzimidazoles showed poor 
BBB permeability and inconsistent distribution with NR2B subunit, [125I]8 may be 
partially bound to the NR2B subunit under in vivo condition. Compound 8 may be a 
potential scaffold for further structural modification to develop novel imaging probes of 
cerebral NMDA receptors. 
 
4. Experimental Section 
 
4.1. General information. 
 
1H NMR spectra were recorded on a JNM-GSX-270WB spectrometer (270 MHz; 
JEOL, Tokyo, Japan), using tetramethylsilane as an internal standard. Fast atom 
bombardment mass spectra (FAB-MS) were obtained on a JMS-AX505H spectrometer 
(JEOL). Electrospray ionization mass spectra (ESI-MS) were obtained on a TSQ 7000 
(Thermo Fisher Scientific, California, USA). High-resolution mass spectra (HRMS) 
were obtained on a QSTAR®XL MS/MS System with the use of ESI. [125I]NaI was 
purchased from MP Biomedicals (California, USA). All other chemicals used were 
reagent grade. All animals were supplied by Japan SLC (Hamamatsu, Japan). An 
automated gamma counter with a NaI(Tl) detector (ARC-2000; Aloka, Tokyo, Japan) 
was used to measure radioactivity. The present animal study was approved by the 
Animal Care and Use Committee of the Hamamatsu University School of Medicine. 
 
4.1.1. Ethyl 2-{4-(4-bromobenzyl)piperidin-1-yl} acetate (4) 
To a solution of 323 (13.0 g, 51.15 mmol) in DMF (8.0 ml), diisopropylethylamine 
(10.65 ml, 61.26 mmol) and ethyl bromoacetate (6.84 ml, 61.26 mmol) were added, and 
the reaction mixture was stirred at room temperature for 3 h. EtOAc (50 ml) was added 
to the mixture, and the organic layers were washed with aqueous NaHCO3 and brine, 
dried with Na2SO4, and evaporated to dryness. The crude product was chromatographed 
on silica gel with hexane/EtOAc = 2:1 to provide 4 (12.4 g, 36.44 mmol, 71 %) as a 
colorless oil, 1H NMR (CDCl3) δ: 7.38 (2 H, d, J= 8.43 Hz), 7.01 (2 H, d, J= 8.42 Hz), 
4.17 (2 H, q, J= 7.33 Hz), 3.17 (2 H, s), 2.90 (2 H, d, J= 11.92 Hz), 2.48 (2 H, d, J= 6.59 
Hz), 2.10 (2 H, t, J= 11.54 Hz), 1.58-1.33 (5 H, m), 1.26 (3 H, t, J= 7.15 Hz), ESI-MS 
m/z; 340 (M+H)+.  
 
4.1.2. Ethyl 2-{4-(4-tributylstannylbenzyl)piperidin-1-yl} acetate (5) 
To a solution of 4 (5.0 g, 14.69 mmol) in toluene (50 ml), bistributyltin (14.7 ml, 
29.38 mmol) and tetrakis (triphenylphosphine) palladium (509 mg, 0.44 mmol) were 
added, and the reaction mixture was refluxed for 36 h. After cooling, the reaction 
mixture was filtered through celite. The filtrate was evaporated to dryness. The crude 
product was chromatographed on silica gel with hexane/EtOAc = 3:1 to provide 5 (4.30 
g, 7.75 mmol, 53 %) as a colorless oil, 1H NMR (CDCl3) δ: 7.35 (2 H, d, J= 7.35 Hz), 
7.09 (2 H, d, J= 7.90 Hz), 4.17 (2 H, q, J= 7.16 Hz), 3.17 (2 H, s), 2.91 (2 H, d, J= 11.54 
Hz), 2.50 (2 H, d, J= 6.61 Hz), 2.10 (2 H, t, J= 11.43 Hz), 1.66-1.23 (20 H, m), 
1.06-0.85 (15 H, m), FAB-MS m/z; 552 (M+H)+.  
 
4.1.3. Ethyl 2-{4-(4-iodobenzyl)piperidin-1-yl} acetate (6)  
To a stirred solution of 5 (2.85 g, 5.17 mmol) in carbon tetrachloride (135 mL), 
50 mM solution of iodine in dry carbon tetrachloride (135 mL, 6.72 mmol) was added 
dropwise, and the reaction mixture was allowed to stand at room temperature for 1 h. 
The mixture was evaporated to dryness. The crude product was chromatographed on 
silica gel with hexane/EtOAc = 1:1 to provide 6 (1.36 g, 3.51 mmol, 68 %) as a 
colorless oil, 1H NMR (CDCl3) δ: 7.58 (2 H, d, J= 8.33 Hz), 6.88 (2 H, d, J= 8.33 Hz), 
4.17 (2 H, q, J= 7.08 Hz), 3.17 (2 H, s), 2.90 (2 H, d, J= 11.54 Hz), 2.47 (2 H, d, J= 6.41 
Hz), 2.10 (2 H, t, J= 11.54 Hz), 1.62-1.34 (5 H, m), 1.26 (3 H, t, J= 7.16 Hz), FAB-MS 
m/z; 388 (M+H)+. 
 
4.1.4. 2-{[4-(4-Iodobenzyl)piperidin-1-yl]methyl}-5-methoxybenzimidazole (7)  
Compound 6 (804 mg, 2.08 mmol) was dissolved in 6 M HCl (5 ml), and the 
mixture was heated to 100 °C for 1 h. The reaction mixture was cooled and evaporated 
to dryness. The residue was dissolved in DMF (6 ml), followed by EDC (518 mg, 2.70 
mmol), 1-hydroxy-7-azabenzotriazole (367 mg, 2.70 mmol), triethylamine (570 μl, 4.16 
mmol), and 4-methoxy-1,2-phenylenediamine (287 mg, 2.08 mmol). The reaction 
mixture was stirred at room temperature for 3 h followed by quenching with aqueous 
NaHCO3 and ethyl acetate. Organic layer was separated and washed by brine, dried 
with Na2SO4, and evaporated to dryness. The crude oil was dissolved in acetic acid (6 
ml) and heated to 140 °C for 4 h. The reaction mixture was cooled and evaporated to 
dryness. The crude product was chromatographed on silica gel with CHCl3/MeOH = 20: 
1 to provide 7 (530 mg, 1.15 mmol, 55 %) as a colorless oil, 1H NMR (CDCl3) δ: 7.59 
(2 H, d, J= 8.12 Hz), 7.46 (1 H, d, J= 7.91 Hz), 7.04 (1 H, s), 6.88 (1 H, d, J= 8.12 Hz), 
6.87 (1 H, d, J= 7.98 Hz), 3.85 (5 H, s), 2.93 (2 H, d, J= 12.18 Hz), 2.51 (2 H, d, J= 6.41 
Hz), 2.21 (2 H, t, J= 11.33 Hz), 1.68-1.25 (5 H, m), ESI-MS m/z; 462 (M+H)+.  
 
4.1.4. 2-{[4-(4-Iodobenzyl)piperidin-1-yl]methyl}benzimidazol-5-ol (8) 
Compound 7 (530 mg, 1.15 mmol) was dissolved in HBr/H2O (48 %, 10 ml), and 
the mixture was heated to 100 °C for 6 h. The reaction mixture was cooled and 
evaporated to dryness. The crude product was chromatographed on silica gel with 
CHCl3/MeOH/NH4OH= 200: 10: 1 to provide 8 (324 mg, 0.724 mmol, 63 %) as a white 
solid, mp= 117-118 °C, 1H NMR (CDCl3) δ: 7.67 (1 H, dd, J= 8.66, 1.01 Hz), 7.63 (2 H, 
d, J= 8.55 Hz), 7.16-7.12 (2 H, m), 6.99 (2 H, d, J= 8.34 Hz), 4.77 (2 H, s), 3.63 (2 H, d, 
J= 11.97), 3.26-3.17 (1 H, m), 2.58 (d, J= 6.84 Hz), 1.95-1.90 (4 H, m), 1.66-1.60 (2 H, 
m), ESI-HRMS (m/z) calcd for C20H23IN3O, 448.0880 (M+H)
+, obsd 448.0829.  
   
4.1.5. N-{2-[4-(4-Iodobenzyl)-piperidin-1-ylmethyl]benzoimidazol-5-yl}- 
methanesulfonamide (9) 
Using the above procedure for 7 with N-(3,4-diaminophenyl) 
methanesulfonamide,20 the title compound 9 (27 mg, 0.052 mmol, 53 %) was obtained 
as a white solid, mp = 92-94 °C, 1H NMR (CD3OD) δ: 7.58 (2 H, d, J= 8.34 Hz), 7.50 
(1 H, d, J= 8.12 Hz), 7.49 (1 H, dd, J= 2.08, 0.48 Hz), 7.13 (1 H, dd, J= 8.66, 2.04 Hz), 
6.93 (2 H, d, J= 7.91 Hz), 3.75 (2 H, s), 3.32 (2 H, d, J= 10 .47 Hz), 2.90 (3 H, s), 2.50 
(2 H, d, J= 6.62 Hz), 2.11 (2 H, t, J= 10.69 Hz), 1.64-1.20 (5 H, m), ESI-HRMS (m/z) 
calcd for C21H26IN4O2S, 525.0821 (M+H)
+, obsd 525.0769. 
 
4.1.6. Ethyl 2-{4-(4-Iodophenoxy)piperidin-1-yl} acetate (11) 
     Compound 10 (686 mg, 1.70 mmol)25 was dissolved in 30 % TFA/CH2Cl2 (5 ml), 
and the mixture was stirred at room temperature for 5 h followed by evaporated to 
dryness. The crude product was converted to the title compound 11 using the above 
procedure for compound 4. In result, compound 11 (300 mg, 45 %) was obtained as a 
colorless oil, 1H NMR (CDCl3) δ: 7.53 (2 H, d, J= 8.98 Hz), 6.68 (2 H, d, J= 8.98 Hz), 
4.30 (1 H, quin, J= 3.85 Hz), 4.19 (2 H, q, J= 7.09 Hz), 3.24 (2 H, s), 2.83-2.75 (2 H, m), 
2.58-2.47 (2 H, m), 2.05-1.97 (2 H, m), 1.91-1.84 (2 H, m), ESI-MS m/z; 390 (M+H)+.  
 
4.1.7. 2-{[4-(4-Iodophenoxy)piperidin-1-yl]methyl}-5-methoxybenzimidazole (12)  
      Using the above procedure for 7 starting from compound 11, the title compound 
12 (96 mg, 0.207 mmol, 73 %) was obtained as a yellow solid, mp = 50-52 °C, 1H NMR 
(CD3OD) δ: 7.53 (2 H, d, J= 8.97 Hz), 7.41 (1 H, d, J= 8.76 Hz), 7.04 (1 H, d, J= 2.13 
Hz), 6.86 (1 H, dd, J= 8.76, 2.57 Hz), 6.73 (2 H, d, J= 8.98 Hz), 4.38 (1 H, quin, J= 3.74 
Hz), 3.83 (3 H, s), 3.79 (2 H, s), 2.85-2.77 (2 H, m), 2.51-2.41 (2 H, m), 2.07-1.98 (2 H, 
m), 1.87-1.77 (2 H, m), ESI-MS m/z; 164 (M+H)+.  
. 
4.1.8. 2-{[4-(4-Iodophenoxy)piperidin-1-yl]methyl}benzimidazol-5-ol (13) 
Using the above procedure for 8 starting from compound 12, the title compound 
13 (108 mg, 0.241 mmol, 77 %) was obtained as a white solid, mp = 63-65 °C, 1H NMR 
(CD3OD) δ: 7.53 (2 H, d, J= 8.98 Hz), 7.34 (1 H, d, J= 8.55 Hz), 6.90 (1 H, d, J= 2.25 
Hz), 6.74 (1 H, dd, J= 8.45, 2.68 Hz), 6.73 (2 H, d, J= 8.97 Hz), 4.38 (1 H, quin, J= 3.63 
Hz), 3.76 (2 H, s), 2.86-2.76 (2 H, m), 2.49-2.41 (2 H, m), 2.07-1.99 (2 H, m), 1.86-1.77 
(2 H, m), ESI-HRMS (m/z) calcd for C19H21IN3O2, 450.679 (M+H)
+, obsd 450.0621. 
 
4.1.9.2-{[4-(4-Trimethylstannylbenzyl)piperidin-1-yl]methyl}benzimidazol-5-ol (14)  
To a solution of 8 (50 mg, 0.125 mmol) in toluene (3 ml), bistrimethyltin (104 μl, 
0.502 mmol) and tetrakis (triphenylphosphine) palladium (15 mg, 0.013 mmol) were 
added, and the reaction mixture was refluxed for 6 h. After cooling, the reaction mixture 
was filtered through celite. The filtrate was evaporated to dryness. The crude product 
was chromatographed on silica gel with CHCl3/MeOH = 15:1 to provide 14 (32 mg, 
0.066 mmol, 53 %) as a colorless oil, 1H NMR (CDCl3) δ: 7.41 (1 H, d, J= 8.80 Hz), 
7.39 (2 H, d, J= 8.06 Hz), 7.08 (2 H, d, J= 7.69 Hz), 7.04 (1 H, d, J= 2.20 Hz), 
6.83 (1 H, dd, J= 8.80, 2.20 Hz), 4.09 (2 H, s), 3.11 (2 H, d, J= 12.09 Hz), 2.53 (2 H, d, 
J= 5.87 Hz), 2.47 (2 H, t, J= 11.73 Hz), 1.77-1.51 (5 H, m), 0.27 (9 H, s), FAB-MS m/z; 
486 (M+H)+.  
4.1.10. N-{2-[4-(4-Trimethylstannylbenzyl)-piperidin-1-ylmethyl]benzoimidazol- 
5-yl}- methanesulfonamide (15) 
Using the above procedure for 14 starting from compound 9, the title compound 
15 (5.2 mg, 9.26 μmol, 97 %) was obtained as a colorless oil, 1H NMR (CDCl3) δ: 
7.57-7.53 (2 H, m), 7.40 (2 H, d, 7.91 Hz), 7.18 (1 H, d, 8.33 Hz), 7.10 (2 H, d, 7.70 Hz), 
3.78 (2 H, s), 2.97 (3 H, s), 2.86 (2 H, d, J= 11.12 Hz), 2.54 (2 H, d, J= 6.62 Hz), 2.14 (2 




[125I]8 and [125I]9 were prepared by similar method described in the literature.26 In 
brief, 30 % aqueous hydrogen peroxide (100 μl) was added to a mixture of [125I] NaI 
(60 μl, 19.4-41.4 MBq, carrier-free), 1 % HCl (40 μl), and trimethylstannyl precursor 14, 
15 (0.1 mg in 100 μl of ethanol) in a sealed vial. The mixture was allowed to react for 
40 min at room temperature and then quenched with 10 % aqueous sodium bisulfite 
(100 μl). EtOAc (5 ml) was added to the mixture, and the organic layers were washed 
with aqueous brine, and evaporated to dryness. The crude products were purified by 
HPLC (column; Nacalai Cosmosil 5C18-AR II, 10×250 mm, mobile phase; MeOH: 
0.1 % TFA in H2O= 60: 40, flow rate: 3.0 ml/min). Each fraction was collected and the 
solvent was removed in vacuo. Radiochemical purity was assayed to be >98% by 
analytical HPLC (column; Nacalai Cosmosil 5C18-ARII, 4.6 × 250 mm, mobile phase; 
MeOH: 0.1 % TFA in H2O= 55: 45, flow rate: 1.0 ml/min). The radiochemical yields 
based on [125I] NaI were 85-90 and 78-81 % for [125I]8 and [125I]9, respectively.    
 
4.3. In vitro binding assays 
 
The Ki values of benzimidazoles for binding of [3H]ifenprodil to rat cortical 
membrane homogenates were determined by the method mentioned in the literature.25 
In brief, well washed membranes (200–300 μg of protein) in 20 mM HEPES-KOH 
buffer (pH 7.4), were incubated with [3H]ifenprodil (4.0 nM) with either buffer or 
displacing drug added to make a final volume of 500 μl for 120 min at 25 °C. In each 
experiment the assay buffer contained 100 mM trifluoroperazine. Non-specific binding 
was defined by the addition of unlabeled ifenprodil at 1 mM. Bound ligands were 
collected by rapid filtration using a Brandel cell harvester onto glass fiber filter (GF/B). 
The filters were washed rapidly three times with 2.5 ml of ice-cold assay buffer. 
Following separation and rinsed, the filters were placed into scintillation liquid (4 ml; 
ASCII, GE Healthcare Bio-Sciences) and radioactivity was determined with a liquid 
scintillation counter. 
 
4.4. In vitro receptor autoradiography 
 
The brain sagittal sections, obtained by the method described in the literature,13  
were pre-incubated for 30 min at 25 °C in 50 mM Tris–HCl buffer (pH 7.4 at 25 °C) 
containing 5% bovine serum albumin (BSA). These were subsequently incubated in the 
same buffer containing [125I]8 or [125I]9 (300 kBq, 0.09-0.14 nM) at 25 °C for 30 min. 
The slices were rinsed triplicate for 3 min each with cold (5 °C) incubation buffer 
containing 1 % BSA, and subsequently dipped into cold water. The sections were dried 
under a steam of warm air and placed in contact with 125I-sensitive imaging plates 
(BAS-SR 2040; Fuji Photo. Film, Tokyo, Japan) for 3 days. Distributions of 
radioactivity on the plates were analyzed by Bio-Image Analyzer (FLA-3000; Fuji 
Photo. Film, Tokyo, Japan), which were photographically visualized as shown in Figure 
2A–D. Regions of interest (ROIs) on the slices were placed on the cerebral cortex, 
hippocampus, and cerebellum; and the radioactivities in these regions were expressed as 
photostimulated luminescence (PSL) values on ROI-background PSL value per square 
millimeter. The specific binding was determined as the difference between total binding 
and binding in the presence of the corresponding non-radioactive benzimidazoles (10 
μM). Receptor selectivity studies were performed as similar procedure in the presence 
of several drugs (10 μM). 
 
4.5. In vivo experiments 
 
The [125I] benzimidazoles (0.1 ml, ca. 14.8 kBq for whole body distribution 
studies, ca. 148 kBq for regional brain distribution studies) were injected intravenously 
via tail vein into ddY mice (Male, 6W, 30-35 g). At the designated time intervals, the 
mice were killed and their organs were dissected. The brain was further divided into the 
cerebral cortex, hippocampus and cerebellum. The tissues were then weighed and the 
radioactivity was measured by automated gamma counting. Data were calculated as the 
percentage of the injected dose per gram of tissue (%dose/g).  
To assess the in vivo specific binding of [125I]8, the non-radioactive 8 or NR2B 
antagonist Ro-25,6981 (3 mg/kg in 10 % DMSO/saline) was given as pre-treatment by 
intravenous injection 30 min before [125I]8 administration. Mice were killed 180 min 
after injection. The modulation of [125I]8 by P-gp and OAT in vivo was evaluated 
according to the literature.36,52,53 In brief, CsA {50 mg/kg in a mixture of cremophor EL 
(140 mg/ml) and ethanol (5 %) /saline} or probenecid (200 mg/kg in 5 % sodium 
bicarbonate/saline) was given as pre-treatment by intravenous injection 30 min before 
[125I]8 administration. Mice were killed 180 min after injection of [125I]8. In each of the 
control mouse, the same amount of drug-free corresponding solvent was injected. 
 To assess the metabolism of [125I] benzimidazoles in the mouse brain, the mice 
were killed at 180 min after [125I] benzimidazoles (185 kBq) injection. Whole brains 
were quickly removed, homogenized with ice-cooled MeOH (1.0 ml), and centrifuged 
at 1,750 g for 10 min at 4 °C. The metabolites in MeOH extract were analyzed by 
radio-TLC using CHCl3/MeOH = 9:1 and EtOAc: EtOH= 1:1 for [
125I]8, CHCl3/EtOH 
= 4:1 and EtOAc: EtOH= 4:1 for [125I]9, as mobile phases. 
 
4.6. Partition coefficient determination 
 
Partition coefficient between n-octanol and buffer was measured by a 
conventional shake flask method in triplicate. The benzimidazoles (1–2 mg) were well 
shaken in a mixture of n-octanol (1 ml) and 10 mM phosphate buffer (pH 7.4, 1 ml) for 
15 min at ambient temperature. After centrifugation (2500 rpm for 5 min) of the mixture, 
the two layers were separated and analyzed by HPLC (column; Nacalai Cosmosil 
5C18-AR 300, 4.6 × 250 mm, mobile phase; MeOH: 0.1 % TFA in H2O = 50: 50, flow 
rate; 1.0 ml/min) to obtain log D (pH 7.4) values (Table 1). 
 
4.7. Data analysis 
 
Data were expressed as the mean ± standard deviation. In vitro experiments of 
[125I]8 and [125I]9 were statistically analyzed by Mann–Whitney U-test as shown in 
Figure 2. In vivo experiments of [125I] 8 were analyzed by the Kruskal–Wallis test with 
Dunn’s multiple comparison post-test as shown in Figure 4 or Mann–Whitney U-test as 
shown in Table 4. A value of P < 0.05 was considered statistically significant. 
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Table 1 In vitro binding affinity (Ki) of new benzimidazole derivatives for the NR2B 
subtype of the NMDA receptor and octanol/phosphate buffer distribution coefficient 









a Data from Ref. 20. The assay was inhibition study of 3H-[(E)-N1-(2-methoxybenzyl) 
cinnamamidine] binding to hNR1a/NR2B receptors expressed in Ltk- cells. 
 
b The Ki values were obtained by the method in Ref. 25. Each value (mean ± SD) was 
determined triplicate using rat cortical membrane homogenates in HEPES-KOH buffer. 
 
c The partition coefficient between n-octanol and sodium phosphate buffer at pH=7.4 



















Compounds R1 R2 X Kia (nM) log D7.4
c
Ifenprodil 20.0 ± 4.89
1a OH H 1.50 3.09 ± 0.22
8 OH I CH2 7.28 ± 2.93 3.95
9 NHSO2Me I CH2 5.75 ± 1.19 3.54
13 OH I O 32.5 ± 16.3 3.74
Kib (nM)
Table 2 Effects of drugs on in vitro binding of [125I]benzimidazoles to rat brain slices.  








Table 3 Biodistribution data for 125I labeled benzimidazoles in normal ddY mice.a 
a [125I]Benzimidazoles (14.8 kBq) were injected intravenously via tail vein into ddY 





Cerebral cortex Hippocampus Cerebellum Cerebral cortex Hippocampus Cerebellum
Ro-25,6981 58.3 50.9 91.8 58.1 59.0 89.3
Prazosin 95.6 92.6 102.9 92.8 95.5 97.0




[ 125 I] 8
Blood 3.22 ± 0.58 1.15 ± 0.06 0.67 ± 0.11 0.75 ± 0.13 0.30 ± 0.11 0.28 ± 0.11
Liver 14.68 ± 3.50 25.03 ± 4.20 28.99 ± 6.31 30.50 ± 6.60 32.22 ± 6.56 30.16 ± 1.83
Kidney 5.35 ± 0.91 12.20 ± 3.18 11.20 ± 2.65 10.34 ± 1.60 7.74 ± 1.32 5.46 ± 0.67
Intestine 4.02 ± 0.64 1.83 ± 0.33 2.39 ± 0.79 2.35 ± 0.47 4.55 ± 1.03 5.89 ± 1.05
Stomach 0.72 ± 0.16 1.93 ± 0.40 2.54 ± 0.81 2.16 ± 0.24 2.51 ± 0.55 2.17 ± 0.75
Spleen 0.50 ± 0.32 5.66 ± 1.25 5.91 ± 1.25 4.65 ± 0.51 4.25 ± 0.69 3.79 ± 0.43
Pancreas 0.49 ± 0.13 5.74 ± 2.45 6.10 ± 1.42 6.35 ± 1.25 6.53 ± 1.95 8.76 ± 0.37
Heart 1.47 ± 0.29 5.39 ± 0.33 2.31 ± 0.48 1.87 ± 0.41 1.58 ± 0.16 1.58 ± 0.11
Lung 6.60 ± 0.95 14.48 ± 2.52 8.16 ± 2.37 7.54 ± 2.19 4.75 ± 0.33 3.44 ± 0.80
Brain 0.21 ± 0.03 0.42 ± 0.06 0.44 ± 0.07 0.48 ± 0.09 0.56 ± 0.06 0.55 ± 0.14
Brain-to-blood ratio 0.07 ± 0.02 0.36 ± 0.03 0.67 ± 0.12 0.64 ± 0.06 1.99 ± 0.57 2.23 ± 0.99
[ 125 I] 9
Blood 4.74 ± 1.59 0.95 ± 0.40 0.53 ± 0.08 0.54 ± 0.08 0.55 ± 0.12 0.36 ± 0.10
Liver 4.60 ± 2.69 19.35 ± 9.22 16.67 ± 2.84 13.74 ± 1.72 17.81 ± 4.07 10.93 ± 2.51
Kidney 3.26 ± 1.64 10.99 ± 4.46 8.79 ± 0.91 8.52 ± 1.98 15.23 ± 2.31 10.51 ± 1.97
Intestine 0.55 ± 0.31 1.58 ± 0.75 3.07 ± 0.50 3.79 ± 0.69 7.82 ± 1.22 6.49 ± 1.77
Stomach 0.42 ± 0.22 1.28 ± 0.47 2.24 ± 0.46 2.40 ± 1.05 4.04 ± 0.83 3.56 ± 1.28
Spleen 0.90 ± 0.61 3.19 ± 1.43 2.91 ± 0.42 2.78 ± 0.57 2.85 ± 0.74 1.60 ± 0.26
Pancreas 0.92 ± 0.46 3.09 ± 1.59 3.71 ± 0.69 4.55 ± 1.14 5.39 ± 1.18 3.72 ± 0.59
Lung 9.07 ± 5.18 5.83 ± 1.29 4.29 ± 0.32 4.35 ± 0.38 6.93 ± 0.36 3.62 ± 0.21
Heart 3.82 ± 1.65 3.52 ± 2.19 1.86 ± 0.94 1.70 ± 0.73 1.61 ± 2.29 0.93 ± 0.55
Brain 0.32 ± 0.12 0.44 ± 0.19 0.50 ± 0.07 0.52 ± 0.07 0.67 ± 0.08 0.47 ± 0.09
Brain to Blood ratio 0.07 ± 0.01 0.46 ± 0.09 0.94 ± 0.13 1.00 ± 0.26 1.23 ± 0.16 1.34 ± 0.28
0.5 min 360 min5 min 30 min 60 min 180 min
Table 4 The modulation of BBB permeability of [125I]8 by P-glycoprotein.a  
 
 
a Regional organ uptake at 180 min after [125I]8 injection. Cyclosporin A (50 mg/kg) 
was given as pre-treatment by intravenous injection 30 min before [125I]8 (148 kBq) 








Table 5 The modulation of BBB permeability of [125I]8 by organic anion transporter.a 
 
 
a Regional organ uptake at 180 min after [125I]8 injection. Probenecid (200 mg/kg) was 
given as pre-treatment by intravenous injection 30 min before [125I]8 (148 kBq) 
administration.  
Values were presented as mean±S.D. (%dose/g, n= 5). * P< 0.05 in comparison to the 

















R1= OMe             7
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Scheme 1. Preparation of benzylpiperidine derivatives (8 and 9).  
Reagent and conditions: (a) ethyl bromoacetate, diisopropylethylamine, DMF, r.t., 71 %; 
(b) (Bu3Sn)2, (Ph3P)4Pd, toluene, 110 
oC, 53 %; (c) I2, CCl4, r.t., 68 %; (d) 1) HCl, 100 
oC, 2) EDC, HOAt, triethylamine, 4-substituted phenylenediamine, DMF, r.t., 3) acetic 
acid, 140 oC, 55 % for 7, 53 % for 9; (e) HBr/H2O, 100 



























Scheme 2. Preparation of phenoxypiperidine derivative (13).  
Reagent and conditions: (a) 1) TFA, CH2Cl2, r.t., 2) ethyl bromoacetate, 
diisopropylethylamine, DMF, r.t., 45 %; (b) 1) HCl, 100 oC, 2) EDC, HOAt, 
triethylamine, 4-substituted phenylenediamine, DMF, r.t., 3) acetic acid, 140 oC, 73 %; 



















R1= OH               8
R1= NHSO2Me    9
a b
R1= OH                14
R1= NHSO2Me    15
R1= OH                [
125I]8
R1= NHSO2Me    [
125I]9  
 
Scheme 3. Preparation of [125I]8 and [125I]9.  
Reagent and conditions: (a) (Me3Sn)2, (Ph3P)4Pd, toluene, 110 
oC, 53 % for 14 and 97 % 
for 15; (b) [125I]NaI, H2O2, HCl, EtOH, r.t., 85-90 % for [


















































R2= Me, F, Cl
1 2
1a; R1= OH, R2= H
 
 
Figure 3. Autoradiogram of in vitro total binding (TB) of [125I]8 (A), nonspecific 
binding (NBS) of [125I]8 (B), total binding of [125I]9 (C), and nonspecific binding of 
[125I]9 (D) to rat brain sagittal sections. The quantified values of [125I]8 (E) and [125I]9 
(F) in the cerebral cortex, hippocampus, and cerebellum were expressed as 
(PSL-BG)/mm2 (mean±SD, n = 4–6). Nonspecific binding was determined in the 
presence of corresponding nonradioactive benzimidazoles (10 μM). 










































Figure 4. Regional brain uptake of [125I]8 (A) and [125I]9 (B) in normal ddY mice. 
[125I]Benzimidazoles (148 kBq) were injected intravenously via mice tail vein. 
 
Figure 5. Effects of non-radioactive 8 and Ro-25,6981 (NR2B antagonist) on the blood 
concentration (A), liver uptake (B), regional brain uptake (C), and brain tissue to blood 
ratio (D) of [125I]8 in mice at 180 min after injection. Drugs (3 mg/kg) were given as 
pre-treatment by intravenous injection 30 min before [125I]8 (148 kBq) administration. 
Values were presented as mean±S.D. (%dose/g, n= 5). * P<0.01 in comparison to the 
control group (Kruskal-Wallis test, post test was Dunn’s test). 
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